Personal tools

Coexpression cluster:C260: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
No edit summary
No edit summary
Line 1: Line 1:
{{Coexpression_clusters
{{Coexpression_clusters
|coexpression_dpi_cluster_scores_median=0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1.03259415282711,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
|full_id=C260_acute_chronic_Natural_NK_Basophils_biphenotypic_blood
|full_id=C260_acute_chronic_Natural_NK_Basophils_biphenotypic_blood
|gostat_on_coexpression_clusters=GO:0008934!inositol-1(or 4)-monophosphatase activity!0.026484607892999!3612$GO:0031403!lithium ion binding!0.026484607892999!3612$GO:0006661!phosphatidylinositol biosynthetic process!0.026484607892999!3612$GO:0030246!carbohydrate binding!0.0316981286456445!2591;947$GO:0042605!peptide antigen binding!0.0316981286456445!445347$GO:0004653!polypeptide N-acetylgalactosaminyltransferase activity!0.0316981286456445!2591$GO:0044459!plasma membrane part!0.0316981286456445!445347;221692;947$GO:0042287!MHC protein binding!0.0316981286456445!445347$GO:0046488!phosphatidylinositol metabolic process!0.0316981286456445!3612$GO:0008376!acetylgalactosaminyltransferase activity!0.0316981286456445!2591$GO:0050900!leukocyte migration!0.0316981286456445!947$GO:0004864!protein phosphatase inhibitor activity!0.0316981286456445!221692$GO:0019212!phosphatase inhibitor activity!0.0316981286456445!221692$GO:0046489!phosphoinositide biosynthetic process!0.0316981286456445!3612$GO:0005975!carbohydrate metabolic process!0.0316981286456445!3612;2591$GO:0046474!glycerophospholipid biosynthetic process!0.0379820699667983!3612$GO:0009897!external side of plasma membrane!0.0388471879066574!947$GO:0004437!inositol or phosphatidylinositol phosphatase activity!0.041808238422943!3612$GO:0044425!membrane part!0.0470009140373129!445347;221692;2591;947$GO:0019888!protein phosphatase regulator activity!0.0470009140373129!221692$GO:0030384!phosphoinositide metabolic process!0.0470009140373129!3612$GO:0005886!plasma membrane!0.0470009140373129!445347;221692;947$GO:0019208!phosphatase regulator activity!0.0470009140373129!221692
|gostat_on_coexpression_clusters=GO:0008934!inositol-1(or 4)-monophosphatase activity!0.026484607892999!3612$GO:0031403!lithium ion binding!0.026484607892999!3612$GO:0006661!phosphatidylinositol biosynthetic process!0.026484607892999!3612$GO:0030246!carbohydrate binding!0.0316981286456445!2591;947$GO:0042605!peptide antigen binding!0.0316981286456445!445347$GO:0004653!polypeptide N-acetylgalactosaminyltransferase activity!0.0316981286456445!2591$GO:0044459!plasma membrane part!0.0316981286456445!445347;221692;947$GO:0042287!MHC protein binding!0.0316981286456445!445347$GO:0046488!phosphatidylinositol metabolic process!0.0316981286456445!3612$GO:0008376!acetylgalactosaminyltransferase activity!0.0316981286456445!2591$GO:0050900!leukocyte migration!0.0316981286456445!947$GO:0004864!protein phosphatase inhibitor activity!0.0316981286456445!221692$GO:0019212!phosphatase inhibitor activity!0.0316981286456445!221692$GO:0046489!phosphoinositide biosynthetic process!0.0316981286456445!3612$GO:0005975!carbohydrate metabolic process!0.0316981286456445!3612;2591$GO:0046474!glycerophospholipid biosynthetic process!0.0379820699667983!3612$GO:0009897!external side of plasma membrane!0.0388471879066574!947$GO:0004437!inositol or phosphatidylinositol phosphatase activity!0.041808238422943!3612$GO:0044425!membrane part!0.0470009140373129!445347;221692;2591;947$GO:0019888!protein phosphatase regulator activity!0.0470009140373129!221692$GO:0030384!phosphoinositide metabolic process!0.0470009140373129!3612$GO:0005886!plasma membrane!0.0470009140373129!445347;221692;947$GO:0019208!phosphatase regulator activity!0.0470009140373129!221692

Revision as of 15:22, 12 September 2012


Full id: C260_acute_chronic_Natural_NK_Basophils_biphenotypic_blood



Phase1 CAGE Peaks

Hg19::chr14:101165430..101165451,-p@chr14:101165430..101165451
-
Hg19::chr14:47722173..47722192,-p@chr14:47722173..47722192
-
Hg19::chr15:54267149..54267170,-p1@ENST00000558920
Hg19::chr15:54267188..54267200,-p2@ENST00000558920
Hg19::chr15:95398778..95398792,+p3@ENST00000556065
Hg19::chr17:55531631..55531640,+p@chr17:55531631..55531640
+
Hg19::chr17:78994695..78994737,-p@chr17:78994695..78994737
-
Hg19::chr18:71468395..71468399,+p@chr18:71468395..71468399
+
Hg19::chr1:1118144..1118151,-p@chr1:1118144..1118151
-
Hg19::chr1:198979759..198979783,-p@chr1:198979759..198979783
-
Hg19::chr1:198999872..198999874,-p@chr1:198999872..198999874
-
Hg19::chr1:208078141..208078145,+p@chr1:208078141..208078145
+
Hg19::chr1:208084565..208084567,+p@chr1:208084565..208084567
+
Hg19::chr1:208084930..208084934,-p22@CD34
Hg19::chr20:25913764..25913768,+p@chr20:25913764..25913768
+
Hg19::chr20:60881514..60881520,+p@chr20:60881514..60881520
+
Hg19::chr2:103038624..103038629,+p@chr2:103038624..103038629
+
Hg19::chr2:127851262..127851291,-p@chr2:127851262..127851291
-
Hg19::chr2:129468319..129468326,-p@chr2:129468319..129468326
-
Hg19::chr2:166651029..166651044,-p11@GALNT3
Hg19::chr2:58967795..58967809,-p@chr2:58967795..58967809
-
Hg19::chr2:71766260..71766282,+p@chr2:71766260..71766282
+
Hg19::chr3:196365912..196365930,+p@chr3:196365912..196365930
+
Hg19::chr4:164871108..164871113,-p@chr4:164871108..164871113
-
Hg19::chr5:118217409..118217420,-p@chr5:118217409..118217420
-
Hg19::chr5:118219344..118219349,-p@chr5:118219344..118219349
-
Hg19::chr5:30850137..30850150,-p@chr5:30850137..30850150
-
Hg19::chr6:12957376..12957395,+p31@PHACTR1
Hg19::chr6:12957417..12957446,+p20@PHACTR1
Hg19::chr6:12957811..12957820,+p37@PHACTR1
Hg19::chr6:30029672..30029686,+p@chr6:30029672..30029686
+
Hg19::chr6:49792450..49792465,-p1@uc003ozv.1
Hg19::chr6:49792495..49792498,-p1@ENST00000430821
Hg19::chr6:5866096..5866110,+p@chr6:5866096..5866110
+
Hg19::chr7:117426647..117426651,-p@chr7:117426647..117426651
-
Hg19::chr7:1274988..1274991,+p@chr7:1274988..1274991
+
Hg19::chr7:1275077..1275088,+p@chr7:1275077..1275088
+
Hg19::chr7:38316320..38316349,-p3@TARP
Hg19::chr7:38358560..38358567,-p2@TRGV9
Hg19::chr7:38358578..38358595,-p1@TRGV9
Hg19::chr7:38370591..38370600,+p@chr7:38370591..38370600
+
Hg19::chr7:38370618..38370628,+p@chr7:38370618..38370628
+
Hg19::chr7:38370646..38370667,+p@chr7:38370646..38370667
+
Hg19::chr7:38370708..38370720,+p@chr7:38370708..38370720
+
Hg19::chr7:73752953..73752964,+p@chr7:73752953..73752964
+
Hg19::chr8:108340337..108340344,+p@chr8:108340337..108340344
+
Hg19::chr8:142555259..142555264,-p@chr8:142555259..142555264
-
Hg19::chr8:142555285..142555291,-p@chr8:142555285..142555291
-
Hg19::chr8:142555297..142555302,-p@chr8:142555297..142555302
-
Hg19::chr8:60173723..60173754,+p@chr8:60173723..60173754
+
Hg19::chr8:82598191..82598195,-p3@IMPA1


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data


GO IDGO nameFDR corrected p-value
GO:0008934inositol-1(or 4)-monophosphatase activity0.026484607892999
GO:0031403lithium ion binding0.026484607892999
GO:0006661phosphatidylinositol biosynthetic process0.026484607892999
GO:0030246carbohydrate binding0.0316981286456445
GO:0042605peptide antigen binding0.0316981286456445
GO:0004653polypeptide N-acetylgalactosaminyltransferase activity0.0316981286456445
GO:0044459plasma membrane part0.0316981286456445
GO:0042287MHC protein binding0.0316981286456445
GO:0046488phosphatidylinositol metabolic process0.0316981286456445
GO:0008376acetylgalactosaminyltransferase activity0.0316981286456445
GO:0050900leukocyte migration0.0316981286456445
GO:0004864protein phosphatase inhibitor activity0.0316981286456445
GO:0019212phosphatase inhibitor activity0.0316981286456445
GO:0046489phosphoinositide biosynthetic process0.0316981286456445
GO:0005975carbohydrate metabolic process0.0316981286456445
GO:0046474glycerophospholipid biosynthetic process0.0379820699667983
GO:0009897external side of plasma membrane0.0388471879066574
GO:0004437inositol or phosphatidylinositol phosphatase activity0.041808238422943
GO:0044425membrane part0.0470009140373129
GO:0019888protein phosphatase regulator activity0.0470009140373129
GO:0030384phosphoinositide metabolic process0.0470009140373129
GO:0005886plasma membrane0.0470009140373129
GO:0019208phosphatase regulator activity0.0470009140373129



Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>


Cell Type
Ontology termp-valuen
hematopoietic stem cell2.32e-36172
angioblastic mesenchymal cell2.32e-36172
hematopoietic cell4.50e-33182
hematopoietic oligopotent progenitor cell9.65e-33165
hematopoietic multipotent progenitor cell9.65e-33165
leukocyte8.51e-22140
myeloid cell4.63e-20112
common myeloid progenitor4.63e-20112
nongranular leukocyte8.58e-19119
hematopoietic lineage restricted progenitor cell3.36e-18124
lymphoid lineage restricted progenitor cell4.51e-1252
T cell5.57e-1225
pro-T cell5.57e-1225
lymphocyte9.12e-1253
common lymphoid progenitor9.12e-1253
myeloid leukocyte6.03e-0976
mature alpha-beta T cell1.35e-0818
alpha-beta T cell1.35e-0818
immature T cell1.35e-0818
mature T cell1.35e-0818
immature alpha-beta T cell1.35e-0818
myeloid lineage restricted progenitor cell5.36e-0870
CD8-positive, alpha-beta T cell6.51e-0811
granulocyte monocyte progenitor cell1.02e-0771
CD14-positive, CD16-negative classical monocyte2.75e-0742
monopoietic cell7.41e-0763
monocyte7.41e-0763
monoblast7.41e-0763
promonocyte7.41e-0763
Uber Anatomy
Ontology termp-valuen
hematopoietic system1.06e-11102
blood island1.06e-11102
hemolymphoid system7.90e-10112
adult organism2.33e-09115
blood5.96e-0715
haemolymphatic fluid5.96e-0715
organism substance5.96e-0715
Disease
Ontology termp-valuen
leukemia1.07e-1939
hematologic cancer7.88e-1751
immune system cancer7.88e-1751
myeloid leukemia2.36e-1631


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data


No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data